New Gene Mutation Associated with Fanconi Anemia
|
By LabMedica International staff writers Posted on 25 Jul 2017 |

Image: The enzyme E3 ubiquitin ligase (RFWD3) helps target other proteins on single-stranded DNA for degradation. B: Cells lacking RFWD3 show DNA repair defects (Photo courtesy of Julius-Maximilians-Universität).
Fanconi anemia is a rare genetic disease characterized by bone marrow failure heralded by low platelet counts and unusually large red blood cells. Mutations in over 20 genes have been identified as causative for Fanconi anemia, which encode proteins commonly involved in DNA repair mechanisms.
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Latest Molecular Diagnostics News
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
- Machine-Learning Genetic Risk Score Improves Early Prediction of Type 1 Diabetes
- Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
- CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
- Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
- Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
- Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
- Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








